Modality
mRNA
MOA
KIF18Ai
Target
TROP-2
Pathway
Autophagy
Wet AMD
Development Pipeline
Preclinical
Jan 2024
→ Mar 2030
PreclinicalCurrent
NCT06736380
1,203 pts·Wet AMD
2024-01→2030-03·Not yet recruiting
1,203 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-284.0y awayInterim· Wet AMD
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Not yet…
Catalysts
Interim
2030-03-28 · 4.0y away
Wet AMD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06736380 | Preclinical | Wet AMD | Not yet recr... | 1203 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| BMR-8526 | BioMarin | Phase 1/2 | CD38 |